Related Experiment Videos
[Hematopoietic stem cell transplantation in multiple myeloma]
Jorge Vela-Ojeda1, Miriam A García Ruiz-Esparza
1Hospital de Especialidades Centro Médico La Raza, IMSS. velaj2x@prodigy.net.mx
Summary
Multiple myeloma (MM) treatment has evolved from melphalan-prednisone to high-dose therapy with stem cell support, improving remission rates. Future strategies combine these with novel agents and transplantation for better outcomes.
Area of Science:
- Hematologic Malignancies
- Oncology
- Immunotherapy
Context:
- Multiple myeloma (MM) is a prevalent blood cancer with historically limited treatment efficacy.
- Standard melphalan-prednisone regimens yield poor complete response rates and high chemoresistance.
- Previous combination chemotherapy trials have not improved overall survival.
Purpose:
- To review current and emerging treatment strategies for multiple myeloma.
- To evaluate the effectiveness of high-dose therapy with stem cell support.
- To explore future research directions including novel agents and transplantation.
Summary:
- High-dose therapy with peripheral blood stem cell support offers improved complete remission, event-free, and overall survival rates in MM patients.
- Tandem transplantation with high-dose melphalan is effective in well-resourced centers.
- Future research focuses on combining remission-induction regimens with tandem transplants, maintenance therapies (e.g., thalidomide, idiotype or dendritic cell vaccination), and non-myeloablative allogeneic transplantation.
Impact:
- High-dose therapy and stem cell support represent a significant advancement in MM management.
- Novel agents like thalidomide, bortezomib, and revlimid, combined with transplantation, aim to make MM a manageable chronic disease.
- Potential for achieving long-term remission or cure in a substantial patient subset (30-40%).